[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:oropharyngeal-squamous-cell-carcinoma:cdkn2a-wt-allele":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Oropharyngeal Squamous Cell Carcinoma","CDKN2A wt Allele",18,[8,16,22,28,34,40,46,52,59,65,71,77,83,89,95,101,107,113],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05317000","5-Azacytidine and\u002For Nivolumab in Resectable HPV-Associated HNSCC",[12],"Phase 2","RECRUITING","2026-08-26T02:15:18.897219Z","2026-06-17T02:29:29.995073Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07513389","Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)",[12],"2026-08-26T02:17:45.190188Z","2026-05-29T15:36:40.194242Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05268614","Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma",[12],"2026-08-26T02:17:25.718160Z","2026-05-05T02:43:29.512737Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT06088381","Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)",[12],"2026-08-26T02:18:26.932189Z","2026-05-05T02:43:29.296327Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT05419089","The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)",[12],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:28.852988Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT06323460","Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer",[12],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:28.846466Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":50,"content_modified":51},"NCT05541016","De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA",[12],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:28.485078Z",{"nct_id":53,"title":54,"phases":55,"status":13,"updated_at":57,"content_modified":58},"NCT06563479","A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer",[56],"Phase 3","2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.989005Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT07044635","Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyngeal Squamous Cell Carcinoma.",[12],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.806024Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT03875716","Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma",[],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:27.669935Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT05962242","HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.631667Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT07172256","CUE-101with Pembrolizumab for LA-HPV+HNSCCs",[12],"2026-08-26T02:17:34.833510Z","2026-05-05T02:43:27.601527Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT04852328","Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma",[12],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:26.932385Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":93,"content_modified":94},"NCT07497607","Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma",[12],"2026-08-26T02:15:47.754948Z","2026-04-29T02:57:57.100938Z",{"nct_id":96,"title":97,"phases":98,"status":13,"updated_at":99,"content_modified":100},"NCT04564989","Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC",[],"2026-08-26T02:18:57.189473Z","2026-05-13T02:55:06.254087Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":105,"content_modified":106},"NCT06356272","Oropharynx (OPX) Biomarker Trial",[],"2026-08-26T02:15:10.362237Z","2026-05-13T02:55:06.483201Z",{"nct_id":108,"title":109,"phases":110,"status":13,"updated_at":111,"content_modified":112},"NCT06532279","Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer",[12],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:28.872744Z",{"nct_id":114,"title":115,"phases":116,"status":118,"updated_at":119,"content_modified":120},"NCT07428148","Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma",[117],"Phase 1\u002FPhase 2","NOT_YET_RECRUITING","2026-08-26T02:19:05.360997Z","2026-04-29T02:57:57.115905Z"]